Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reported fourth quarter 2024 financial results that exceeded revenue expectations but fell short on earnings per share. The company’s stock edged up 1.3% following the announcement.
The biopharmaceutical firm, focused on developing treatments for central nervous system diseases, posted Q4 revenue of $174.2 million, surpassing the analyst consensus of $150.24 million. However, earnings per share came in at $0.27, missing estimates of $0.33.
Supernus saw strong growth in its key products during the quarter. Net sales of Qelbree, used to treat attention-deficit/hyperactivity disorder (ADHD), surged 60% YoY to $74.4 million. GOCOVRI, for Parkinson’s disease, increased 15% to $36.9 million.
"Our 2024 results reflect solid commercial execution across the company, including continued growth of our core products, and strong growth in operating earnings," said Jack Khattar, President and CEO of Supernus.
For the full year 2024, total revenues rose 9% to $661.8 million. The company reported operating earnings of $81.7 million, compared to an operating loss of $5.3 million in 2023.
Looking ahead, Supernus provided 2025 guidance for total revenues between $600 million and $630 million. The company expects operating earnings (loss) between $(15) million and $10 million.
Supernus also announced FDA approval for ONAPGO, its treatment for motor fluctuations in adults with advanced Parkinson’s disease. The company plans to launch ONAPGO in the second quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.